Literature DB >> 26552698

High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion.

Dominic W Chung1, Junmei Chen2, Minhua Ling2, Xiaoyun Fu3, Teri Blevins2, Scott Parsons2, Jennie Le2, Jeff Harris2, Thomas R Martin4, Barbara A Konkle3, Ying Zheng5, José A López6.   

Abstract

The ability of von Willebrand factor (VWF) to initiate platelet adhesion depends on the number of monomers in individual VWF multimers and on the self-association of individual VWF multimers into larger structures. VWF self-association is accelerated by shear stress. We observed that VWF self-association occurs during adsorption of VWF onto surfaces, assembly of secreted VWF into hyperadhesive VWF strings on the endothelial surface, and incorporation of fluid-phase VWF into VWF fibers. VWF adsorption under static conditions increased with increased VWF purity and was prevented by a component of plasma. We identified that component as high-density lipoprotein (HDL) and its major apolipoprotein ApoA-I. HDL and ApoA-I also prevented VWF on the endothelium from self-associating into longer strands and inhibited the attachment of fluid-phase VWF onto vessel wall strands. Platelet adhesion to VWF fibers was reduced in proportion to the reduction in self-associated VWF. In a mouse model of thrombotic microangiopathy, HDL also largely prevented the thrombocytopenia induced by injection of high doses of human VWF. Finally, a potential role for ApoA-I in microvascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the inverse relationship between the concentration of ApoA-I and that of hyperadhesive VWF. These results suggest that interference with VWF self-association would be a new approach to treating thrombotic disorders.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26552698      PMCID: PMC4742551          DOI: 10.1182/blood-2014-09-599530

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.

Authors:  Anil K Chauhan; Janka Kisucka; Colin B Lamb; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

Review 2.  Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Authors:  Joel L Moake
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

3.  von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.

Authors:  A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom
Journal:  J Thromb Haemost       Date:  2006-10-16       Impact factor: 5.824

4.  Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation.

Authors:  Stefan Barlage; Carsten Gnewuch; Gerhard Liebisch; Zsuzsanna Wolf; Franz-Xaver Audebert; Thomas Glück; Dieter Fröhlich; Bernhard K Krämer; Gregor Rothe; Gerd Schmitz
Journal:  Intensive Care Med       Date:  2009-08-08       Impact factor: 17.440

Review 5.  Recent advances in thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler; Joel L Moake; Toshiyuki Miyata; James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

6.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.

Authors:  Silvia Ferrari; Friedrich Scheiflinger; Manfred Rieger; Geert Mudde; Martine Wolf; Paul Coppo; Jean-Pierre Girma; Elie Azoulay; Christian Brun-Buisson; Fadi Fakhouri; Jean-Paul Mira; Eric Oksenhendler; Pascale Poullin; Eric Rondeau; Nicolas Schleinitz; Benoit Schlemmer; Jean-Louis Teboul; Philippe Vanhille; Jean-Paul Vernant; Dominique Meyer; Agnès Veyradier
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.

Authors:  B Savage; E Saldívar; Z M Ruggeri
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

8.  Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network.

Authors:  Alexej Barg; Rainer Ossig; Tobias Goerge; Matthias F Schneider; Hermann Schillers; Hans Oberleithner; Stefan W Schneider
Journal:  Thromb Haemost       Date:  2007-04       Impact factor: 5.249

9.  Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress.

Authors:  Jing Huang; Robyn Roth; John E Heuser; J Evan Sadler
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

Review 10.  Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.

Authors:  Göran Walldius; Ingmar Jungner
Journal:  Curr Opin Cardiol       Date:  2007-07       Impact factor: 2.161

View more
  26 in total

1.  von Willebrand factor self-association is regulated by the shear-dependent unfolding of the A2 domain.

Authors:  Changjie Zhang; Anju Kelkar; Sriram Neelamegham
Journal:  Blood Adv       Date:  2019-04-09

2.  Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols.

Authors:  Jenny K McDaniel; Mohammad S Abdelgawwad; Audra Hargett; Matthew B Renfrow; Khalil Bdeir; Wenjing Cao; Douglas B Cines; X Long Zheng
Journal:  J Thromb Haemost       Date:  2019-03-13       Impact factor: 5.824

Review 3.  Platelets and von Willebrand factor in atherogenesis.

Authors:  Melinda D Wu; Tamara M Atkinson; Jonathan R Lindner
Journal:  Blood       Date:  2017-02-07       Impact factor: 22.113

Review 4.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

5.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

Review 6.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

7.  Specific electrostatic interactions between charged amino acid residues regulate binding of von Willebrand factor to blood platelets.

Authors:  Gianluca Interlandi; Olga Yakovenko; An-Yue Tu; Jeff Harris; Jennie Le; Junmei Chen; José A López; Wendy E Thomas
Journal:  J Biol Chem       Date:  2017-09-18       Impact factor: 5.157

Review 8.  Utility of microfluidic devices to study the platelet-endothelium interface.

Authors:  Jevgenia Zilberman-Rudenko; Joanna L Sylman; Kathleen S Garland; Cristina Puy; Andrew D Wong; Peter C Searson; Owen J T McCarty
Journal:  Platelets       Date:  2017-03-30       Impact factor: 3.862

Review 9.  The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.

Authors:  Jessica Hurtubise; Krystie McLellan; Kevin Durr; Oluwadara Onasanya; Daniel Nwabuko; Joseph Fomusi Ndisang
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

10.  Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Authors:  Malay Kumar Basu; Felipe Massicano; Lijia Yu; Konstantine Halkidis; Vikram Pillai; Wenjing Cao; Liang Zheng; X Long Zheng
Journal:  Thromb Haemost       Date:  2020-11-12       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.